Breaking: Adamas Pharmaceuticals (NASDAQ:ADMS) “Buy” Rating Maintained by Analysts at Mizuho Securities Today; The Price Target Given is $70.0000

June 23, 2018 - By Clifton Ray

Adamas Pharmaceuticals, Inc. (NASDAQ:ADMS) Logo

Adamas Pharmaceuticals (NASDAQ:ADMS) Rating Reaffirmed

Recently, In analysts report issued on Friday morning, Adamas Pharmaceuticals (NASDAQ:ADMS) shares have had their “Buy” Rating restate by equity analysts at Mizuho Securities, who currently has a $70.0000 target price per share on company. This target by Mizuho Securities would indicate the possibile upside of 177.67 % from the current price.

Adamas Pharmaceuticals, Inc. (NASDAQ:ADMS) Ratings Coverage

Among 6 analysts covering Adamas Pharmaceuticals (NASDAQ:ADMS), 6 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. Adamas Pharmaceuticals has $85.0 highest and $3100 lowest target. $52.33’s average target is 107.58% above currents $25.21 stock price. Adamas Pharmaceuticals had 11 analyst reports since January 23, 2018 according to SRatingsIntel. The stock of Adamas Pharmaceuticals, Inc. (NASDAQ:ADMS) earned “Buy” rating by Mizuho on Tuesday, January 23. The firm earned “Buy” rating on Thursday, April 19 by Mizuho. Needham maintained the stock with “Buy” rating in Friday, February 23 report. Piper Jaffray maintained the shares of ADMS in report on Tuesday, January 30 with “Buy” rating. The rating was maintained by Mizuho with “Buy” on Friday, June 22. The rating was maintained by Mizuho on Tuesday, February 20 with “Buy”. The stock of Adamas Pharmaceuticals, Inc. (NASDAQ:ADMS) has “Buy” rating given on Tuesday, February 20 by Evercore. Mizuho maintained Adamas Pharmaceuticals, Inc. (NASDAQ:ADMS) on Friday, March 9 with “Buy” rating. The firm earned “Buy” rating on Wednesday, April 4 by Leerink Swann. Piper Jaffray maintained it with “Buy” rating and $49.0 target in Thursday, February 22 report.

The stock decreased 1.14% or $0.29 during the last trading session, reaching $25.21. About 462,582 shares traded. Adamas Pharmaceuticals, Inc. (NASDAQ:ADMS) has risen 88.75% since June 23, 2017 and is uptrending. It has outperformed by 76.18% the S&P500.

Analysts await Adamas Pharmaceuticals, Inc. (NASDAQ:ADMS) to report earnings on August, 14. They expect $-1.44 earnings per share, down 54.84 % or $0.51 from last year’s $-0.93 per share. After $-1.35 actual earnings per share reported by Adamas Pharmaceuticals, Inc. for the previous quarter, Wall Street now forecasts 6.67 % negative EPS growth.

Adamas Pharmaceuticals, Inc., a pharmaceutical company, discovers, develops, and sells chrono-synchronous therapies for chronic neurologic disorders. The company has market cap of $680.22 million. The company's product portfolio comprises ADS-5102, a chrono-synchronous amantadine therapy for the treatment of levodopa-induced dyskinesia in patients with Parkinson's disease. It currently has negative earnings. The Company’s portfolio also comprises of Namzaric capsules; and Namenda XR (memantine hydrochloride) extended release capsules for the treatment of moderate to severe Alzheimer's disease.

More news for Adamas Pharmaceuticals, Inc. (NASDAQ:ADMS) were recently published by: Globenewswire.com, which released: “Adamas Announces New Employment Inducement Grant” on June 08, 2018. Nasdaq.com‘s article titled: “Adamas Presents New Data Analysis Demonstrating that GOCOVRIâ„¢ Reduces Transitions between Dyskinesia and …” and published on June 22, 2018 is yet another important article.

Adamas Pharmaceuticals, Inc. (NASDAQ:ADMS) Ratings Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: